Stone JH, Frigault MJ, Serling-Boyd NJ, et al. - Researchers investigated whether interleukin-6 receptor blockade would be efficacious for hospitalized patients suffering from coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation, in this randomized, double-blind, placebo-controlled trial. Enrolled patients were 243 in total, including 141 (58%) men and 102 (42%) women with a median age of 59.8 years. The participants were randomized (2:1) to receive standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo. Intubation or death, evaluated in a time-to-event analysis, was the primary outcome. Considering the findings of this study, experts concluded the non-effectiveness of tocilizumab as a prophylactic for intubation or death in moderately ill hospitalized patients with Covid-19. Due to wide confidence intervals for efficacy comparisons, some advantage or harm could not be ruled out.